The European Commission (EC) has approved Roche’s Alecensa (alectinib) as the first adjuvant treatment for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) post-tumour resection with high recurrence risk. The decision follows the positive results from the Phase III ALINA clinical trial. The gold standard of business intelligence.
The active-controlled, randomised, open-label, multicentre trial assessed the safety and efficacy of adjuvant Alecensa versus platinum-based chemotherapy. The trial included 257 patients randomly assigned to either the Alecensa or the chemotherapy treatment arm, with disease-free survival as the primary endpoint. Alecensa showed a 76% decline in the disease recurrence or mortality risk compared to chemotherapy.
An exploratory analysis also suggested an improvement in central nervous system disease-free survival, a crucial benefit for ALK-positive NSCLC patients who are more likely to develop brain metastases. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The safety profile of Alecensa in the trial was in line with previous studies without any unexpected safety findings.